Skip to main content

Table 2 Cox regression analyses for determining outcome based on the expression of ALDH2, CCNE1 and SMAD3

From: Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma

Variables No. patients Univariate Multivariate
   p-valuea HR (95% CI) p-valueb HR (95% CI)
Sex      
 Female 26 0.98 0.99 (0.39-2.51) 0.92 1.05 (0.40-2.73)
 Male 77     
Age 32-87 years 0.96 1.00 (0.96-1.04) 0.97 1.00 (0.96-1.04)
T stage      
 T1 62 7.32 × 10-06 0.10 (0.03-0.27) 7.27 × 10-06 0.09 (0.03-0.27)
 T2 16 0.12 0.413 (0.14-1.26) 0.12 0.41 (0.13-1.26)
 T3 25     
ALDH2      
 Low 54 1.69 × 10-04 52.02 (6.63-407.94) 2.11 × 10-04 81.91 (7.96-842.24)
 High 49     
CCNE1      
 Low 59 4.53 × 10-04 41.4 (5.17-331.66) 6.38 × 10-04 36.27 (4.24-309.92)
 High 44     
SMAD3      
 Low 62 9.51 × 10-04 31.14 (4.05-239.33) 1.04 × 10-03 61.90 (5.80-660.64)
 High 41     
  1. aP-value and hazard ration (HR) were calculated for each variable using Cox regression model. Sex: female vs. male; Age: continuous variable and range of age is shown instead of number of patients; T stage: T1 vs. T3, T2 vs. T3; ALDH2: low vs. high; CCNE1 and SMAD3: high vs. low. bP-value and HR of each molecular marker were adjusted for clinicopathological factors and determined separately with Cox regression model.